The worldwide outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a global pandemic. Alongside vaccines, antiviral therapeutics is an important part of the healthcare response to counter the ongoing threat presented by COVID-19.
In this video, we are going to learn about Pfizer’s oral SARS-COV2 inhibitor Paxlovid (PF-07321332 with Ritonavir) that has been shown to reduce the risk of hospitalization or death by 89% in an interim analysis of phase 2/3 EPIC-HR study. Because of the strong potency and excellent safety profile of the drug, Pfizer plans to submit the data to the U.S. FDA for Emergency Use Authorization as soon as possible.
The oral antiviral treatment, together with existing COVID vaccines, could potentially put an end to one of the worst pandemics in human history that has killed more than 5 million people so far. We will hear what Pfizer’s CEO Albert Bourla has to say about the drug. More importantly, I will provide a detailed analysis of how SARS-COV2 self-replicates and how the new drug works to stop one of the key processes.